Literature DB >> 22902412

RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization.

Seunghyung Lee1, Jeremy G T Wurtzel, Sharad S Singhal, Sanjay Awasthi, Lawrence E Goldfinger.   

Abstract

RalBP1/RLIP76 is a widely expressed multifunctional protein that binds the Ral and R-Ras small GTPases. In the mouse, RLIP76 is nonessential but its depletion or blockade promotes tumorigenesis and heightens the sensitivity of normal and tumor cells to radiation and cytotoxic drugs. However, its pathobiologic functions, which support tumorigenesis, are not well understood. Here, we show that RLIP76 is required for angiogenesis and for efficient neovascularization of primary solid tumors. Tumor growth from implanted melanoma or carcinoma cells was blunted in RLIP76(-/-) mice. An X-ray microcomputed tomography-based method to model tumor vascular structures revealed defects in both the extent and form of tumor angiogenesis in RLIP76(-/-) mice. Specifically, tumor vascular volumes were diminished and vessels were fewer in number, shorter, and narrower in RLIP76(-/-) mice than in wild-type mice. Moreover, we found that angiogenesis was blunted in mutant mice in the absence of tumor cells, with endothelial cells isolated from these animals exhibiting defects in migration, proliferation, and cord formation in vitro. Taken together, our results establish that RLIP76 is required for efficient endothelial cell function and angiogenesis in solid tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902412      PMCID: PMC3473090          DOI: 10.1158/0008-5472.CAN-12-0468

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  An Eps homology (EH) domain protein that binds to the Ral-GTPase target, RalBP1.

Authors:  A Yamaguchi; T Urano; T Goi; L A Feig
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

2.  Biological behavior of malignant melanoma cells correlated to their survival in vivo.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

3.  A putative effector of Ral has homology to Rho/Rac GTPase activating proteins.

Authors:  S H Park; R A Weinberg
Journal:  Oncogene       Date:  1995-12-07       Impact factor: 9.867

4.  An improved MTT assay using the electron-coupling agent menadione.

Authors:  H Garn; H Krause; V Enzmann; K Drössler
Journal:  J Immunol Methods       Date:  1994-02-10       Impact factor: 2.303

Review 5.  The role of angiogenesis in tumor growth.

Authors:  J Folkman
Journal:  Semin Cancer Biol       Date:  1992-04       Impact factor: 15.707

6.  Purification and characterization of an ATPase from human liver which catalyzes ATP hydrolysis in the presence of the conjugates of bilirubin bile acids and glutathione.

Authors:  Y C Awasthi; S S Singhal; S Gupta; H Ahmad; P Zimniak; A Radominska; R Lester; R Sharma
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

7.  Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity.

Authors:  V Jullien-Flores; O Dorseuil; F Romero; F Letourneur; S Saragosti; R Berger; A Tavitian; G Gacon; J H Camonis
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

8.  Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture.

Authors:  J S Bertram; P Janik
Journal:  Cancer Lett       Date:  1980-11       Impact factor: 8.679

9.  Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein.

Authors:  S Awasthi; S S Singhal; S K Srivastava; P Zimniak; K K Bajpai; M Saxena; R Sharma; S A Ziller; E P Frenkel; S V Singh
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

10.  Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases.

Authors:  S B Cantor; T Urano; L A Feig
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

View more
  30 in total

1.  Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

Authors:  N B Volz; S Stintzing; W Zhang; D Yang; Y Ning; T Wakatsuki; R E El-Khoueiry; J E Li; A Kardosh; F Loupakis; C Cremolini; A Falcone; S J Scherer; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2014-07-29       Impact factor: 3.550

2.  Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth.

Authors:  James V Michael; Jeremy G T Wurtzel; Guang Fen Mao; A Koneti Rao; Mikhail A Kolpakov; Abdelkarim Sabri; Nicholas E Hoffman; Sudarsan Rajan; Dhanendra Tomar; Muniswamy Madesh; Marvin T Nieman; Johnny Yu; Leonard C Edelstein; Jesse W Rowley; Andrew S Weyrich; Lawrence E Goldfinger
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

3.  Three-dimensional reconstruction of neovasculature in solid tumors and basement membrane matrix using ex vivo X-ray microcomputed tomography.

Authors:  Seunghyung Lee; Mary F Barbe; Rosario Scalia; Lawrence E Goldfinger
Journal:  Microcirculation       Date:  2014-02       Impact factor: 2.628

4.  RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells.

Authors:  Seunghyung Lee; Lawrence E Goldfinger
Journal:  FASEB J       Date:  2014-06-13       Impact factor: 5.191

5.  P300 regulates the human RLIP76 promoter activity and gene expression.

Authors:  Archana Sehrawat; Sushma Yadav; Yogesh C Awasthi; Alakananda Basu; Charles Warden; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2013-02-16       Impact factor: 5.858

6.  The RLIP76 N-terminus binds ARNO to regulate PI 3-kinase, Arf6 and Rac signaling, cell spreading and migration.

Authors:  Seunghyung Lee; Jeremy G T Wurtzel; Lawrence E Goldfinger
Journal:  Biochem Biophys Res Commun       Date:  2014-10-30       Impact factor: 3.575

Review 7.  RLIP76 Targeted Therapy for Kidney Cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; James Figarola; David Horne; Sanjay Awasthi
Journal:  Pharm Res       Date:  2015-05-29       Impact factor: 4.200

Review 8.  Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer.

Authors:  Sharad S Singhal; Divya Jain; Preeti Singhal; Sanjay Awasthi; Jyotsana Singhal; David Horne
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-28       Impact factor: 10.680

Review 9.  RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.

Authors:  Sharad S Singhal; Lokesh Nagaprashantha; Preeti Singhal; Sulabh Singhal; Jyotsana Singhal; Sanjay Awasthi; David Horne
Journal:  Pharm Res       Date:  2017-04-06       Impact factor: 4.200

10.  The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis.

Authors:  Junsong Zhou; Yi Wu; Lu Wang; Lubica Rauova; Vincent M Hayes; Mortimer Poncz; David W Essex
Journal:  J Clin Invest       Date:  2015-11-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.